Cellectis S.A. (CLLS)
Company Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.
The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL.
The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products.
Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Country | France |
Founded | 1999 |
IPO Date | Feb 7, 2007 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 231 |
CEO | Dr. Andre Choulika Ph.D. |
Contact Details
Address: 8 Rue De La Croix Jarry Paris, Lle-de-france, I0 75013 France | |
Phone | 33181691600 |
Website | cellectis.com |
Stock Details
Ticker Symbol | CLLS |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001627281 |
CUSIP Number | 15117K103 |
ISIN Number | US15117K1034 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Andre Choulika Ph.D. | Co-Founder, Chief Executive Officer and Director |
Dr. David j. d. Sourdive Ph.D. | Deputy Chief Executive Officer, Executive Vice President of CMC and Manufacturing and Director |
Dr. Bing C. Wang M.B.A., Ph.D. | Chief Financial Officer |
Valerie Cros | Principal Financial Officer and Principal Accounting Officer |
Jean Charles Epinat | Chief Technological Officer |
Dr. Philippe Duchateau Ph.D. | Chief Scientific Officer |
Stephan Reynier M.Sc. | Chief Regulatory and Pharmaceutical Compliance Officer |
Marie-Bleuenn Terrier | General Counsel and Secretary of the Board of Directors |
Pascalyne Wilson | Director of Communications |
Kyung Nam-Wortman | Executive Vice President and Chief Human Resources Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 16, 2024 | 6-K | Report of foreign issuer |
Dec 22, 2023 | 6-K | Report of foreign issuer |
Dec 22, 2023 | 6-K | Report of foreign issuer |
Dec 5, 2023 | 6-K | Report of foreign issuer |
Dec 5, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 17, 2023 | 6-K | Report of foreign issuer |
Nov 17, 2023 | 6-K | Report of foreign issuer |
Nov 16, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |